Katherine Stueland Sells 1,078 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 1,078 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $89.44, for a total value of $96,416.32. Following the completion of the sale, the chief executive officer now owns 6,674 shares in the company, valued at $596,922.56. The trade was a 13.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total transaction of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The stock was sold at an average price of $94.73, for a total transaction of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08.

GeneDx Price Performance

Shares of WGS opened at $90.79 on Wednesday. The business’s fifty day moving average is $84.57 and its 200 day moving average is $70.78. GeneDx Holdings Corp. has a 12-month low of $7.72 and a 12-month high of $115.60. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The stock has a market cap of $2.55 billion, a P/E ratio of -46.32 and a beta of 1.91.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66. The firm had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

WGS has been the subject of several recent analyst reports. TD Cowen raised their price objective on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group lifted their price target on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $72.33.

Institutional Trading of GeneDx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in WGS. California State Teachers Retirement System boosted its position in shares of GeneDx by 13.3% during the fourth quarter. California State Teachers Retirement System now owns 11,384 shares of the company’s stock valued at $875,000 after buying an additional 1,335 shares during the last quarter. Polar Asset Management Partners Inc. bought a new position in GeneDx during the 4th quarter valued at $1,007,000. Palisades Investment Partners LLC purchased a new position in GeneDx during the 4th quarter worth $6,425,000. Castleark Management LLC purchased a new position in GeneDx during the 4th quarter worth $4,743,000. Finally, PharVision Advisers LLC bought a new stake in shares of GeneDx in the 4th quarter worth $301,000. 61.72% of the stock is owned by institutional investors.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.